• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在别构位点上开启和关闭 Aurora-A 激酶。

Switching Aurora-A kinase on and off at an allosteric site.

机构信息

Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, UK.

Department of Molecular and Cell Biology, University of Leicester, UK.

出版信息

FEBS J. 2017 Sep;284(18):2947-2954. doi: 10.1111/febs.14069. Epub 2017 Apr 18.

DOI:10.1111/febs.14069
PMID:28342286
Abstract

Protein kinases are central players in the regulation of cell cycle and signalling pathways. Their catalytic activities are strictly regulated through post-translational modifications and protein-protein interactions that control switching between inactive and active states. These states have been studied extensively using protein crystallography, although the dynamic nature of protein kinases makes it difficult to capture all relevant states. Here, we describe two recent structures of Aurora-A kinase that trap its active and inactive states. In both cases, Aurora-A is trapped through interaction with a synthetic protein, either a single-domain antibody that inhibits the kinase or a hydrocarbon-stapled peptide that activates the kinase. These structures show how the distinct synthetic proteins target the same allosteric pocket with opposing effects on activity. These studies pave the way for the development of tools to probe these allosteric mechanisms in cells.

摘要

蛋白激酶是细胞周期和信号通路调控的核心分子。它们的催化活性受到严格的翻译后修饰和蛋白-蛋白相互作用的调控,这些调控控制着激酶在无活性和有活性状态之间的转换。尽管蛋白激酶的动态性质使得很难捕捉到所有相关的状态,但这些状态已经通过蛋白质晶体学得到了广泛的研究。在这里,我们描述了两个最近的 Aurora-A 激酶结构,它们捕获了激酶的活性和无活性状态。在这两种情况下,Aurora-A 都是通过与合成蛋白的相互作用而被捕获的,这些合成蛋白要么是抑制激酶的单域抗体,要么是激活激酶的碳氢化合物订书肽。这些结构显示了不同的合成蛋白如何以相反的方式靶向相同的变构口袋,从而对活性产生影响。这些研究为开发在细胞中探测这些变构机制的工具铺平了道路。

相似文献

1
Switching Aurora-A kinase on and off at an allosteric site.在别构位点上开启和关闭 Aurora-A 激酶。
FEBS J. 2017 Sep;284(18):2947-2954. doi: 10.1111/febs.14069. Epub 2017 Apr 18.
2
Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2.极光激酶A自身磷酸化及其被TPX2变构激活的分子机制。
Elife. 2014 May 27;3:e02667. doi: 10.7554/eLife.02667.
3
A TPX2 Proteomimetic Has Enhanced Affinity for Aurora-A Due to Hydrocarbon Stapling of a Helix.一种TPX2拟肽由于螺旋的烃类钉合作用而对极光激酶A具有增强的亲和力。
ACS Chem Biol. 2016 Dec 16;11(12):3383-3390. doi: 10.1021/acschembio.6b00727. Epub 2016 Nov 1.
4
Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.定量构象分析揭示了激酶抑制剂对 Aurora 激酶激活态选择性的起源。
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E11894-E11903. doi: 10.1073/pnas.1811158115. Epub 2018 Dec 5.
5
Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain.合成的可变结构域抗体对极光激酶A的变构抑制作用
Open Biol. 2016 Jul;6(7). doi: 10.1098/rsob.160089.
6
Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?小分子靶向 Aurora A 激酶:迈向下一代药物的一步?
Curr Med Chem. 2019;26(13):2234-2242. doi: 10.2174/0929867324666170727120315.
7
Identification of small molecule inhibitors of the Aurora-A/TPX2 complex.极光激酶A/TPX2复合物小分子抑制剂的鉴定
Oncotarget. 2017 May 9;8(19):32117-32133. doi: 10.18632/oncotarget.16738.
8
Characterization of Three Druggable Hot-Spots in the Aurora-A/TPX2 Interaction Using Biochemical, Biophysical, and Fragment-Based Approaches.使用生化、生物物理和基于片段的方法对极光激酶A/TPX2相互作用中的三个可成药热点进行表征。
ACS Chem Biol. 2017 Nov 17;12(11):2906-2914. doi: 10.1021/acschembio.7b00537. Epub 2017 Oct 30.
9
Computationally-guided optimization of small-molecule inhibitors of the Aurora A kinase-TPX2 protein-protein interaction.极光激酶A-TPX2蛋白-蛋白相互作用小分子抑制剂的计算引导优化
Chem Commun (Camb). 2017 Aug 17;53(67):9372-9375. doi: 10.1039/c7cc05379g.
10
Drugging MYCN through an allosteric transition in Aurora kinase A.通过 Aurora 激酶 A 的变构跃迁来抑制 MYCN。
Cancer Cell. 2014 Sep 8;26(3):414-427. doi: 10.1016/j.ccr.2014.07.015. Epub 2014 Aug 28.

引用本文的文献

1
Suppressive role of fukutin on cell proliferation in uterine cervical carcinoma in relation to Aurora-A kinase.福库汀在子宫颈癌中对细胞增殖的抑制作用与极光激酶A的关系。
Histol Histopathol. 2025 Oct;40(10):1555-1568. doi: 10.14670/HH-18-889. Epub 2025 Feb 19.
2
The significant others of aurora kinase a in cancer: combination is the key.极光激酶A在癌症中的重要关联因素:联合治疗是关键。
Biomark Res. 2024 Sep 27;12(1):109. doi: 10.1186/s40364-024-00651-4.
3
Aurora-A condensation mediated by BuGZ aids its mitotic centrosome functions.
由BuGZ介导的Aurora-A凝聚有助于其有丝分裂中心体功能。
iScience. 2024 Apr 18;27(5):109785. doi: 10.1016/j.isci.2024.109785. eCollection 2024 May 17.
4
HURP localization in metaphase is the result of a multi-step process requiring its phosphorylation at Ser627 residue.HURP在中期的定位是一个多步骤过程的结果,该过程需要其在Ser627残基处发生磷酸化。
Front Cell Dev Biol. 2023 Jul 5;11:981425. doi: 10.3389/fcell.2023.981425. eCollection 2023.
5
Structural basis for CEP192-mediated regulation of centrosomal AURKA.CEP192 介导的中心体 AURKA 调控的结构基础。
Sci Adv. 2023 Apr 21;9(16):eadf8582. doi: 10.1126/sciadv.adf8582.
6
CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2.CHD1 通过抑制 AURKA 与其共激活因子 TPX2 的相互作用来提高对 Aurora 激酶抑制剂的敏感性。
Cancer Res. 2022 Sep 2;82(17):3088-3101. doi: 10.1158/0008-5472.CAN-22-0631.
7
Design and synthesis of Nrf2-derived hydrocarbon stapled peptides for the disruption of protein-DNA-interactions.设计和合成 Nrf2 衍生的碳氢化合物订书肽以破坏蛋白-DNA 相互作用。
PLoS One. 2022 Jun 22;17(6):e0267651. doi: 10.1371/journal.pone.0267651. eCollection 2022.
8
Aurora A and AKT Kinase Signaling Associated with Primary Cilia.极光 A 和 AKT 激酶信号与初级纤毛相关。
Cells. 2021 Dec 20;10(12):3602. doi: 10.3390/cells10123602.
9
Bora phosphorylation substitutes in trans for T-loop phosphorylation in Aurora A to promote mitotic entry.Bora 磷酸化在体外替代 Aurora A 的 T 环磷酸化,以促进有丝分裂进入。
Nat Commun. 2021 Mar 26;12(1):1899. doi: 10.1038/s41467-021-21922-w.
10
Allosteric inhibition of LRRK2, where are we now.LRRK2 的变构抑制,我们现在进展如何。
Biochem Soc Trans. 2020 Oct 30;48(5):2185-2194. doi: 10.1042/BST20200424.